BioSpace News Archive

Policy

Aldeyra Anticipates FDA Rejection of Dry Eye Drug Following Regulatory Meeting

Months after a denial of its rare eye cancer injection, Aldeyra Therapeutics is bracing for another potential rejection by the regulator, this time for its investigational dry eye disease treatment.

October 17, 2023
·
2 min read
·
Tristan Manalac
Business

J&J Sees Nearly 7% Growth in Q3, Increases Full-Year Guidance

In its first financial report since the Kenvue consumer health spinoff, Johnson & Johnson beat analyst expectations fueled by strong pharmaceutical sales including Darzalex, Erleada and Stelara.

October 17, 2023
·
2 min read
·
Tristan Manalac
Drug Development

AbbVie’s Skyrizi Beats Remission Rates of J&J’s Stelara in Crohn’s Disease

In a follow-up readout, data from the head-to-head SEQUENCE study showed that AbbVie’s Skyrizi induced better rates of steroid-free remission in Crohn’s disease than Johnson & Johnson’s Stelara.

October 17, 2023
·
2 min read
·
Tristan Manalac
Employer Resources

Talent Acquisition Turns Introspective in a Cooler Market, and Other Things We Learned at LEAP TA: Life Sciences

Life sciences talent acquisition teams are examining internal processes and thinking critically about their employer value proposition as they prepare for innovation and market swings.

October 17, 2023
·
5 min read
·
Chantal Dresner
FDA

Merck Pushes Keytruda into Perioperative NSCLC Setting with FDA Approval

The blockbuster PD-1 inhibitor’s label expanded further on Monday when the FDA greenlit Keytruda as a perioperative treatment for certain patients with earlier stages of non-small cell lung cancer.

October 17, 2023
·
2 min read
·
Tristan Manalac
Policy

How Companies Are Upping Diversity Among Clinical Trial Participants

After the FDA released draft guidance on increasing diversity in clinical trials, companies have been left to figure out the details. Here’s what experts say is working.

October 17, 2023
·
7 min read
·
Sruthi S. Balakrishnan
Business

J&J’s Christopher Whelan on How—and Why—13 Companies Teamed up to Tackle Proteomics

The Pharma Proteomics Project isn’t the first precompetitive collaboration between pharma companies, but it’s one of the largest. Members recently published associations they’ve uncovered in UK Biobank data.

October 17, 2023
·
7 min read
·
Nadia Bey
Zealand Pharma presents data for amylin analog ZP8396 at ObesityWeek

Zealand Pharma A/S announced presentations of clinical and non-clinical results for Zealand’s amylin analog ZP8396 at the Obesity Society Annual Meeting being held in Dallas, Texas from October 14-17, 2023.

October 17, 2023
·
6 min read
Tessellate BIO Emerges from StealthThe Next Generation Synthetic Lethality Precision Oncology Company

Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, has today emerged from stealth, with an initial €8m in seed funding backed by two leading European venture capital firms

October 17, 2023
·
6 min read
Drug Development

AlzeCure Publishes New Article on the GSM Mechanism Behind Alzstatin Against Alzheimer’s Disease

AlzeCure Pharma AB ), a pharmaceutical company that develops candidate drugs for CNS diseases, focusing on Alzheimer’s disease and pain, announced that a new scientific review article on the mechanism underlying the Alzstatin platform has now been published and made available online.

October 17, 2023
·
6 min read